This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Advice regarding using LABAs in chronic asthma

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

In the management of chronic asthma, LABAs should:

  • only be added if regular use of standard-dose ICS has failed to control asthma adequately
  • not be initiated in patients with rapidly deteriorating asthma
  • be introduced as a low dose and the effect properly monitored before considering a dose increase
  • be discontinued in the absence of benefit
  • be reviewed as clinically appropriate: stepping down therapy should be considered when good long-term asthma control has been achieved.

Patients should be asked to report any deterioration in symptoms following initiation of a LABA.

Reference:

  • (1) Medicines and Healthcare products Regulatory Agency. Asthma: long-acting b2 agonists. Accessed from: www.mhra.gov.uk on 12/8/08.

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.